Skip to content
Menu

ADMA Biologics, Inc. ADMA

Full chart Compare
Set alert

Price alert · ADMA

All alert types
13.16 USD -0.18 (-1.32%)

As ofNov 20, 2026, 2:37 PM EST

13.13 Day range 13.29
7.21 52-week range 20.46
YTD
-27.83%
1 year
-19.53%

5D +0.35 (+2.65%)

1313.5014ThuFriMonTueWed13.56
Market cap
2.93B
Revenue (ttm)
519.15M
Profit margin
35.14%
EPS (ttm)
0.77
Shares out
221.85M
P/E ratio
17.13
Forward P/E
14.23
YTD return
-27.83%
1-year return
-19.53%
50-day average
10.82
Volume
1.17M
Avg volume
3.22M
Open
13.22
Previous close
13.34
Day's range
13.13 – 13.29
52-week range
7.21 – 20.46
Beta
0.66
Analysts
Buy
Price target
18.00 (+36.7%)
Earnings date
Feb 24, 2027

Key statistics

200-day average
10.67
Enterprise value
3.09B
Price / sales
5.70
Price / book
6.77
Revenue growth
5.10%
Free cash flow
90.26M
Total cash
124.56M
Total debt
202.80M
Return on equity
41.95%
Short % of float
10.04%

Fundamental scorecard

15 of 25 checks passed on ADMA’s reported financials

ValueGrowthProfitabilityHealthDividend

15of 25 checks passed

  • Value 3 of 5
  • Growth 4 of 5
  • Profitability 3 of 5
  • Financial health 5 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
ADMA Revenue — quarterly 141.10M
ADMA Net income — quarterly 49.88M
ADMA EPS — quarterly 0.22

Earnings

ADMA recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Feb 24, 2027Dec 30, 20260.22———
Nov 4, 2026Sep 30, 20260.19670.23+0.03+16.93%
Aug 5, 2026Jun 30, 20260.16330.160.00-2.02%
May 6, 2026Mar 31, 20260.19330.190.00-1.71%
Feb 25, 2026Dec 31, 20250.1850.20+0.02+8.11%
Nov 5, 2025Sep 30, 20250.160.160.000.00%

Upgrades / downgrades

ADMA analyst upgrades and downgrades
DateFirmActionFromTo
Nov 5, 2026Cantor FitzgeraldmainNeutralNeutral
Jul 15, 2026MizuhomainOutperformOutperform
May 7, 2026Canaccord GenuitymainBuyBuy
May 7, 2026MizuhomainOutperformOutperform
Apr 21, 2026Canaccord Genuityinit—Buy
Apr 13, 2026MizuhomainOutperformOutperform

About ADMA Biologics, Inc.

ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company operates through ADMA BioManufacturing and Plasma Collection Centers segments. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, a human polyclonal antibody product for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics comprising products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

Sector
Healthcare
Industry
Biotechnology
Country
United States

News

Your note

Sign in to keep a note on ADMA — it syncs with the Stock Master app.

Insider holders

ADMA insider holders
InsiderRelationLatest transactionDateShares held
ELMS STEVEN ADirectorPurchaseMar 5, 20260
FINGER ALISON CECILYDirectorStock Award(Grant)Feb 8, 202645,619
GROSSMAN ADAM SChief Executive OfficerConversion of Exercise of derivative securityNov 15, 20263,789,160
GROSSMAN JERROLD BDirectorPurchaseMay 26, 2026612,991
GUIHEEN LAWRENCE PDirectorConversion of Exercise of derivative securityNov 15, 2026186,510
KESTENBERG-MESSINA KAITLIN M.OfficerConversion of Exercise of derivative securityMar 8, 2026466,600

Institution ownership

ADMA institution ownership
Holder% heldSharesValueReported
Blackrock Inc.16.82%37,305,140497.28MSep 29, 2026
State Street Corporation6.16%13,675,348182.29MSep 29, 2026
Rubric Capital Management LP5.57%12,352,584164.66MSep 29, 2026
First Trust Advisors LP4.53%10,041,022133.85MSep 29, 2026
Vanguard Capital Management LLC4.27%9,468,196126.21MSep 29, 2026
Vanguard Portfolio Management LLC4.15%9,207,177122.73MSep 29, 2026

Fund ownership

ADMA fund ownership
Holder% heldSharesValueReported
iShares Trust-iShares Core S&P Small-Cap ETF6.01%13,332,053177.72MSep 29, 2026
First TRT Exch-Trd Fd.-First TRT NYSE Arca Biotechnology Index Fd.4.49%9,970,973132.91MSep 29, 2026
SmallCap World Fund Inc3.84%8,524,390113.63MSep 29, 2026
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund3.17%7,023,20093.62MJun 29, 2026
iShares Trust-iShares Russell 2000 ETF2.69%5,963,00379.49MSep 29, 2026
SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF2.04%4,534,13160.44MSep 29, 2026